The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.

The aim of this study is to describe vascular access complications which are used for therapeutic apheresis in Nephrology.

Complications may include arterio-veinous fistula or graft (AVF or AVG) thrombosis with or without known stenosis; AVF or AVG or central veinous catheter (CVC) infections and CVC dysfunctions.

The investigators may enroll all patients receveing therapeutic apheresis for nephrologic indications in North East France.

Nephrologics indications include :

• acute or active antibody mediated rejection (ABMR),
• Goodpasture disease,
• ANCA vasculitis,
• thrombotic microangiopathy (TMA),
• Focal segmental glomerulosclerosis (FSGS),
• HLA or ABO desensitization for kidney transplantation.

Data inclusion period is from June 2020 to June 2022.

The aim of the study is to describe the proportion and type of complication in the population of patient receving therapeutic apheresis for nephrologic disease in the North East France. Te investigators will study the risk factors that are associated with this complications.

The second aim of the study is to describe the population of patient receving therapeutic apheresis in our unit and in our region.

Inclusion Criteria:

• patients in nephrology receiveing apheresis treatment by filtration or double filtration

Exclusion Criteria:

• apheresis treatment for other indications
• centrifugation apheresis treatment

patients in nephrology receiveing apheresis treatment by filtration or double filtration with arterioveinous fistula or arterioveinous graft or central veinous catheter